Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 14/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17202871 | 0.93 | TRPV4 (0.44) | TRPV4ARCYP11B2CYP11B1PGR | |
| SCHEMBL17202582 | 0.86 | TRPV4 (0.44) | TRPV4ARCYP11B2CYP11B1 | |
| SCHEMBL3854368 | 0.83 | AR (0.42) | TRPV4AR | |
| SCHEMBL3856508 | 0.81 | CCR1 (0.46) | AR | |
| SCHEMBL17202410 | 0.77 | TRPV4 (0.46) | TRPV4CYP11B2CYP11B1PGR | |
| SCHEMBL8476205 | 0.77 | APP (0.52) | TRPV4 | |
| SCHEMBL23215170 | 0.77 | SLC6A3 (0.47) | CYP11B2CYP11B1 | |
| SCHEMBL18501256 | 0.76 | TRPV4 (0.44) | TRPV4CYP11B2CYP11B1PGR | |
| SCHEMBL10535000 | 0.76 | TRPV4 (0.44) | TRPV4ARCYP11B2CYP11B1PGR | |
| SCHEMBL10534920 | 0.75 | TRPV4 (0.43) | TRPV4ARCYP11B2CYP11B1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1252158-B1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| CN-1404481-A | Nicotinamide benzofused heterocyclic derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2003-03-19 | — | — | CN | disclosed |
| EP-1252158-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001057036-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PDE4B, PDE4A, NOX4 | TRPV4 676/4885AR 4219/4885CYP11B2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.